Trial Profile
A Phase II, Multicenter, Randomized, Open-label, Active Controlled Study to Evaluate the Safety and Efficacy of Micafungin Salvage Mono-therapy Versus Active Control Intravenous Salvage Mono-therapy in Patients With Invasive Aspergillosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Micafungin (Primary)
- Indications Aspergillosis; Invasive bronchopulmonary aspergillosis
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 15 Aug 2014 New trial record
- 07 Apr 2009